INT241799

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 4.37
Pain Relevance 0.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (CHIT1) extracellular region (CHIT1) carbohydrate metabolic process (CHIT1)
lysosome (CHIT1)
Anatomy Link Frequency
platelet 5
leukocyte 1
liver 1
brain 1
spleen 1
CHIT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
peripheral neuropathy 25 80.84 Quite High
abdominal pain 4 77.36 Quite High
Paresthesia 4 73.12 Quite High
Pain 49 72.56 Quite High
imagery 28 57.44 Quite High
agonist 1 22.20 Low Low
Central nervous system 16 5.00 Very Low Very Low Very Low
Analgesic 7 5.00 Very Low Very Low Very Low
Inflammation 6 5.00 Very Low Very Low Very Low
tolerance 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Gauchers Disease 402 98.24 Very High Very High Very High
Neurologic Manifestations 18 94.56 High High
Weight Loss 32 94.40 High High
Splenomegaly 17 93.84 High High
Diarrhoea 36 93.76 High High
Hepatomegaly 15 92.24 High High
Disease 91 89.92 High High
Adverse Drug Reaction 8 84.96 Quite High
Peripheral Neuropathy 25 80.84 Quite High
Tremor 17 79.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The level of chitinase decreased in the quebracho group.
Negative_regulation (decreased) of chitinase
1) Confidence 0.42 Published 2010 Journal Proteome Sci Section Body Doc Link PMC3018447 Disease Relevance 0 Pain Relevance 0
Two covariates affected the chitotriosidase decrease under ERT: splenectomy influenced the slope decline and genotype influenced the baseline level (Figure 2b).
Negative_regulation (decrease) of chitotriosidase
2) Confidence 0.24 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945057 Disease Relevance 0.07 Pain Relevance 0
Chitotriosidase levels decreased, without reaching a normal level over a median of six (range, 0 to 15) years of follow-up.
Negative_regulation (decreased) of Chitotriosidase
3) Confidence 0.21 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945057 Disease Relevance 0.10 Pain Relevance 0
For patients given full-dose ERT, platelet counts increased slightly faster, ferritin and TRAP decreased faster, but chitotriosidase and ACE declined more slowly.
Negative_regulation (declined) of chitotriosidase in platelet
4) Confidence 0.15 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945057 Disease Relevance 0.18 Pain Relevance 0
During ERT, clinical abnormality rates decreased (except for neurological involvement) and the biological data improved overall during ERT (increased hemoglobin, leukocyte and platelet levels; decreased chitotriosidase, ACE, TRAP, ferritin and gammaglobulin levels).
Negative_regulation (decreased) of chitotriosidase in platelet
5) Confidence 0.15 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945057 Disease Relevance 0.27 Pain Relevance 0
Platelet counts in nonsplenectomized patients were stable before ERT (+190 platelets/year), while chitotriosidase and TRAP decreased slightly, and ferritin and ACE increased slightly.
Negative_regulation (decreased) of chitotriosidase in Platelet
6) Confidence 0.15 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945057 Disease Relevance 0.32 Pain Relevance 0.09
For some biomarkers, not all patients had the same evolution under ERT: for example, platelet counts rose in 97% of treated patients, while chitotriosidase decreased in 100% and ferritin in 96%, but ACE levels in only 78%.


Negative_regulation (decreased) of chitotriosidase in platelet
7) Confidence 0.15 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945057 Disease Relevance 0.39 Pain Relevance 0
At 6 months, the previously untreated group showed a mean increase in hemoglobin of 0.77 g/dL, platelet count of 41.5 × 109/L or remained stable, and a mean decrease in their chitotriosidase levels of 38.2% (Table 1).
Negative_regulation (decrease) of chitotriosidase in platelet
8) Confidence 0.11 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504062 Disease Relevance 0.80 Pain Relevance 0.14
Chitotriosidase levels decreased by 25.4% over 2 years (Table 1).
Negative_regulation (decreased) of Chitotriosidase
9) Confidence 0.11 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504062 Disease Relevance 0.47 Pain Relevance 0.11
After a total of 12 months’ treatment, spleen and liver volumes, and chitotriosidase levels decreased by only 10%, 6%, and 15%, respectively (Table 1).
Negative_regulation (decreased) of chitotriosidase in liver
10) Confidence 0.10 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504062 Disease Relevance 0.38 Pain Relevance 0.03
Unlike recombinant enzymes, SRT agents are small molecules that can cross the blood-brain barrier.59 Although improved pulmonary function, and a significant decrease in chitotriosidase levels have been observed in patients with GD type 3, miglustat unfortunately, does not appear to have any significant benefits on the neurological manifestations of GD.60
Negative_regulation (decrease) of chitotriosidase in brain associated with gauchers disease and neurologic manifestations
11) Confidence 0.06 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2909498 Disease Relevance 0.75 Pain Relevance 0.04
During ERT, clinical abnormality rates decreased (except for neurological involvement) and the biological data improved overall during ERT (increased hemoglobin, leukocyte and platelet levels; decreased chitotriosidase, ACE, TRAP, ferritin and gammaglobulin levels).
Negative_regulation (decreased) of chitotriosidase in leukocyte
12) Confidence 0.05 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945057 Disease Relevance 0.27 Pain Relevance 0
After a total of 12 months’ treatment, spleen and liver volumes, and chitotriosidase levels decreased by only 10%, 6%, and 15%, respectively (Table 1).
Negative_regulation (decreased) of chitotriosidase in spleen
13) Confidence 0.03 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504062 Disease Relevance 0.38 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox